BR0315931A - Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica - Google Patents
Método de tratar, prevenir ou controlar degeneração macular e composição farmacêuticaInfo
- Publication number
- BR0315931A BR0315931A BR0315931-0A BR0315931A BR0315931A BR 0315931 A BR0315931 A BR 0315931A BR 0315931 A BR0315931 A BR 0315931A BR 0315931 A BR0315931 A BR 0315931A
- Authority
- BR
- Brazil
- Prior art keywords
- macular degeneration
- treating
- preventing
- pharmaceutical composition
- controlling
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000002780 macular degeneration Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Laser Surgery Devices (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODO DE TRATAR, PREVENIR OU CONTROLAR DEGENERAçãO MACULAR E COMPOSIçãO FARMACêUTICA". São descritos métodos de tratamento, prevenção e/ou controle de degeneração macular. Modalidades específicas incluem a administração de um composto imunomodulador, ou de um sal, solvato, hidrato, estereoisómero, clatrato, ou pró-droga farmaceuticamente aceitáveis do mesmo, sozinho ou em combinação com um segundo agente ativo e/ou cirurgia. Também são descritas composições farmacêuticas, formas de dosagem unitárias individuais, e kits adequados para uso nos métodos da invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42289902P | 2002-10-31 | 2002-10-31 | |
PCT/US2003/034661 WO2004041190A2 (en) | 2002-10-31 | 2003-10-31 | Composition for the treatment of macular degenration |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315931A true BR0315931A (pt) | 2005-09-13 |
Family
ID=32312566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0315931-0A BR0315931A (pt) | 2002-10-31 | 2003-10-31 | Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1562597A4 (pt) |
JP (1) | JP2006508950A (pt) |
KR (1) | KR20050061586A (pt) |
CN (1) | CN1732001A (pt) |
AU (1) | AU2003287381B2 (pt) |
BR (1) | BR0315931A (pt) |
CA (1) | CA2504024A1 (pt) |
MX (1) | MXPA05004488A (pt) |
NZ (1) | NZ540186A (pt) |
TW (1) | TWI310312B (pt) |
WO (1) | WO2004041190A2 (pt) |
ZA (1) | ZA200503467B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
EP2838879A1 (en) | 2012-04-20 | 2015-02-25 | Concert Pharmaceuticals Inc. | Deuterated rigosertib |
US9643950B2 (en) | 2012-10-22 | 2017-05-09 | Concert Pharmaceuticals, Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} |
WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
US20180126273A1 (en) * | 2016-11-09 | 2018-05-10 | Agape Assets, LLC | Systems and methods for promoting medication adherence |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
IT1274549B (it) * | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
PT2177517E (pt) * | 1996-07-24 | 2011-11-10 | Celgene Corp | 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
CA2262906C (en) * | 1996-08-12 | 2006-10-31 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
ATE305301T1 (de) * | 1996-11-05 | 2005-10-15 | Childrens Medical Center | Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
US6015803A (en) * | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
CA2336703A1 (en) * | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) * | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
JP2000159761A (ja) * | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2002058730A2 (en) * | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
PT1353672E (pt) * | 2000-11-30 | 2008-01-11 | Childrens Medical Center | Síntese da 4-amino talidomida enantiómeros |
CZ20032098A3 (cs) * | 2001-02-02 | 2004-01-14 | Schering Corporation | 3,4-Disubstituované cyklobuten-1,2-diony a farmaceutický prostředek |
WO2003014315A2 (en) * | 2001-08-06 | 2003-02-20 | The Children's Medical Center Corporation | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
DE60331537D1 (de) * | 2002-05-17 | 2010-04-15 | Celgene Corp | Kombinationen zur behandlung von multiplem myelom |
ES2428354T3 (es) * | 2002-09-18 | 2013-11-07 | Trustees Of The University Of Pennsylvania | Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea |
-
2003
- 2003-10-31 AU AU2003287381A patent/AU2003287381B2/en not_active Ceased
- 2003-10-31 WO PCT/US2003/034661 patent/WO2004041190A2/en active Application Filing
- 2003-10-31 BR BR0315931-0A patent/BR0315931A/pt not_active IP Right Cessation
- 2003-10-31 TW TW092130484A patent/TWI310312B/zh not_active IP Right Cessation
- 2003-10-31 CA CA002504024A patent/CA2504024A1/en not_active Abandoned
- 2003-10-31 JP JP2004550329A patent/JP2006508950A/ja active Pending
- 2003-10-31 MX MXPA05004488A patent/MXPA05004488A/es active IP Right Grant
- 2003-10-31 KR KR1020057007531A patent/KR20050061586A/ko not_active Application Discontinuation
- 2003-10-31 EP EP03781615A patent/EP1562597A4/en not_active Withdrawn
- 2003-10-31 CN CNA200380108093XA patent/CN1732001A/zh active Pending
- 2003-10-31 NZ NZ540186A patent/NZ540186A/en unknown
-
2005
- 2005-04-29 ZA ZA200503467A patent/ZA200503467B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003287381A1 (en) | 2004-06-07 |
CA2504024A1 (en) | 2004-05-21 |
CN1732001A (zh) | 2006-02-08 |
WO2004041190A3 (en) | 2004-09-02 |
WO2004041190A2 (en) | 2004-05-21 |
TW200423936A (en) | 2004-11-16 |
MXPA05004488A (es) | 2005-07-26 |
ZA200503467B (en) | 2006-08-30 |
NZ540186A (en) | 2008-03-28 |
EP1562597A2 (en) | 2005-08-17 |
TWI310312B (en) | 2009-06-01 |
JP2006508950A (ja) | 2006-03-16 |
EP1562597A4 (en) | 2008-05-14 |
AU2003287381B2 (en) | 2008-03-06 |
KR20050061586A (ko) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0415971A (pt) | método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica | |
BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
BRPI0510110A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica | |
BRPI0510166A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica | |
BR0316082A (pt) | Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit | |
BRPI0509400A (pt) | métodos para tratar ou prevenir sono disfuncional, para controlar sono disfuncional e para melhorar o tempo para o começo do sono, a duração do sono ou a qualidade do sono ou realçar a capacidade para levantar sentindo-se renovado depois de um sono noturno, composição farmacêutica, e, kit adequado para o uso no tratamento, prevenção ou controle de sono disfuncional | |
BR0315593A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
BRPI0518282A2 (pt) | uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio | |
BRPI0510167A (pt) | método para tratar, prevenir ou controlar hipertensão pulmonar | |
BRPI0518255A2 (pt) | mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica | |
BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
BR0315315A (pt) | Método para tratar, prevenir ou controlar uma sìndrome mielodisplásica, método para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
BRPI0410306A (pt) | métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit | |
BRPI0519030A2 (pt) | mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica | |
BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
BR0315931A (pt) | Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica | |
BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
BRPI0518062A (pt) | uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
BRPI0409882A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
BR0315609A (pt) | Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica | |
BRPI0409818A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |